David Planchard
Mar 27, 2025, 10:48
David Planchard: Post-Osimertinib Strategies in EGFRmut NSCLC – Savannah and Orchard Studies
David Planchard, Thoracic Pathologist Committee at Gustave Roussy, shared a post on X:
“Two superb post osimertinib studies (Savannah and Orchad) in EGFRmut NSCLC, promising post osimertinib 1L (preferred option) strategies…an important need for our patients!”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 2, 2025, 17:06
Jun 2, 2025, 15:40
Jun 2, 2025, 15:37
Jun 2, 2025, 15:20
Jun 2, 2025, 14:49
Jun 2, 2025, 13:13